Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

Author： Amadori Dino   Silvestrini Rosella   Lena Mario   Boccardo Francesco   Rocca Andrea   Scarpi Emanuela   Schittulli Francesco   Brandi Mario   Maltoni Roberta   Serra Patrizia   Ponzone Riccardo   Biglia Nicoletta   Gianni Lorenzo   Tienghi Amelia   Valerio Maria   Bonginelli Paola   Amaducci Laura   Faedi Marina   Baldini Editta   Paradiso Angelo  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.125, Iss.3, 2011-02, pp. : 775-784

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer

By Colleoni M.   Price K.   Castiglione-Gertsch M.   Goldhirsch A.   Coates A.   Lindtner J.   Collins J.   Gelber R.D.   Thurlimann B.   Rudenstam C.M.  

European Journal of Cancer, Vol. 34, Iss. 11, 1998-10 ,pp. : 1693-1700

Elsevier

Access to resources Recommend Favorite

Upregulation of HER-2/neu by Ovarian Ablation: Results of a Randomized Trial Comparing Leuprorelin to CMF as Adjuvant Therapy in Node-positive Breast Cancer Patients

By Lüftner D.  

Breast Cancer Research and Treatment, Vol. 80, Iss. 3, 2003-08 ,pp. : 245-255

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant Cyclophosphamide, Methotrexate, Fluorouracil (CMF) in Breast Cancer: Is it Cost-effective?

By Norum Jan  

Acta Oncologica, Vol. 39, Iss. 1, 2000-04 ,pp. : 33-39

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: Indirect comparison of dose and schedule in DBCG trials 77, 82, and 89

By Ejlertsen Bent   Mouridsen Henning   Jensen Maj-Britt  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 662-671

Informa Healthcare

Access to resources Recommend Favorite

Health-Related Quality of Life in Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer Patients Undergoing AC Versus CMF Chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23

By Land Stephanie   Kopec Jacek   Yothers Greg   Anderson Stewart   Day Richard   Tang Gong   Ganz Patricia   Fisher Bernard   Wolmark Norman  

Breast Cancer Research and Treatment, Vol. 86, Iss. 2, 2004-07 ,pp. : 153-164

Springer Publishing Company

Access to resources Recommend Favorite